TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00123279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
Study: NCT03091998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD-NP
Description: Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an \~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days
Study: NCT03233334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purpose Project
Description: The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
Study: NCT06600243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistance training + deep sea water
Description: A group that will perform a resistance training protocol with variable resistance and at the same time will receive a supplementation composed by deep sea water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training + Placebo
Description: A group that will perform a resistance training protocol with variable resistance and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control + deep sea water
Description: A group that will maintain their usual live and at the same time will receive a supplementation composed by deep sea water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control + Placebo
Description: A group that will maintain their usual live and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
Study: NCT06332768

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory support
Description: High-flow nasal oxygenation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory support
Description: High-flow nasal oxygenation
Study: NCT04167202

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RICE
Description: RICE protocol
Study: NCT00846430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Interferon alpha-2b
Description: age and weight dependant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib (Celebrex)
Description: age and weight dependant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (temodar)
Description: age and weight dependant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate (Oncovin)
Description: age and weight dependant
Study: NCT01827397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EN41-UGR7C HIV vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study: NCT02496273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL
Description: Mononuclear cells (Dendritic Cell,DC precursor) were isolated from the peripheral blood of gasric cancer by density gradient centrifugation and infected with rAAV/CEA virus.Maturation of the DC was induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor-alpha(TNF-alpha). On day 7, the DCs were collected and mixed with T cells at the ratio of 1 to 20 to induce cytotoxic T lymphocytes (CTL).The cells will be proliferated and infused by intravenous (IV) infusion into the patient.
Study: NCT01036841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin tablet
Description: Administration of desmopressine tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desmopressin MELT formulation
Description: Administration of desmopressine MELT formulation
Study: NCT01828671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Solution 296 mls
Description: Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Solution 296 mls
Description: Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn Tortilla
Description: Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Soy Flour Corn Tortilla
Description: Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Soy Flour Corn Tortilla
Description: Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
Study: NCT02248155

Intervention type: DRUG
Intervention: Pramipexole
Study: NCT03916328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
Study: NCT00737568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF Placebo
Description: TDF placebo tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF Placebo
Description: FTC/TDF placebo tablet administered orally once daily
Study: NCT02251561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FID 109182
Description: Investigational multipurpose contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free Plus
Description: Commercially available multipurpose contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon A contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lens
Description: Commercially available silicone hydrogel contact lens
Study: NCT04407026

Intervention type: BIOLOGICAL
Intervention: biofluids
Description: Gingival crevicular fluid, saliva and serum samples were obtained.

Intervention type: BIOLOGICAL
Intervention: biofluids
Description: Gingival crevicular fluid, saliva and serum samples were obtained.

Intervention type: BIOLOGICAL
Intervention: biofluids
Description: Gingival crevicular fluid, saliva and serum samples were obtained.
Study: NCT03222154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental - Shock wave therapy
Description: Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Shock wave therapy
Description: Simulation of shock wave therapy
Study: NCT00656188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03207321

Intervention type: DIETARY_SUPPLEMENT
Intervention: Upma
Description: A balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma'.
Study: NCT03298984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib
Description: IV bolus followed by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: IV bolus
Study: NCT01975519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105 and Pazopanib
Description: Weekly TRC105 in combination with standard dose Pazopanib.
Study: NCT02966964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWPUR001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWPUR001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00003234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study: NCT01358812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI + Panitumumab
Description: PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL\* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
Study: NCT04042142

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucagon
Description: Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucagon
Description: Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucagon
Description: Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.
Study: NCT03745365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: loop bipartition
Description: A loop gastro-ileostomy 250-300 cm from the ileocecal valve or 200-250 cm from duodeno-jejunal junction was created at the dependent part of the antrum with 2 layers of handsewn suture but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastroileostomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: loop bipartition
Description: A loop gastro-ileostomy 250-300 cm from the ileocecal valve or 200-250 cm from duodeno-jejunal junction was created at the dependent part of the antrum with 2 layers of handsewn suture but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastroileostomy.
Study: NCT01635673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Whole body vibration exercise 3 times per week
Study: NCT03968575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser treatment
Description: sub-threshold micro-pulse laser treatment
Study: NCT04199273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation
Description: Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation
Description: Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
Study: NCT01182805

Intervention type: DEVICE
Group type: OTHER
Intervention: Echocardiography system Ultra DCI Model 5000
Description: Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.

Intervention type: DEVICE
Group type: OTHER
Intervention: Echocardiography machine GE Vivid E9
Description: Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.

Intervention type: DEVICE
Group type: OTHER
Intervention: Diastolic function assessment
Description: Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
Study: NCT01683006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering.
Study: NCT00570037

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent inactivated influenza vaccine
Description: Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
Study: NCT02250807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
Study: NCT06389331

Intervention type: OTHER
Intervention: closed the defect with barbed suture
Description: In direct hernia, content was reduced, and the fascia transversalis (pseudo sac) was pulled and incorporated into closure with a non-absorbable polypropylene barbed monofilament size-0 suture
Study: NCT03263728

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance
Description: Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
Study: NCT04715802

Intervention type: PROCEDURE
Intervention: Immediate breast reconstruction with implant
Description: Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.

Intervention type: PROCEDURE
Intervention: delayed breast reconstruction with implant
Description: The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
Study: NCT03916328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/3TC/EFV or DTG or NVP
Description: A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DMPA
Description: Two thirds of the women will be on DMPA for contraception.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: Two thirds of the women will be on DMPA for contraception.
Study: NCT03018171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Intrathecal clonidine addiction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Intrathecal
Study: NCT03580655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: Avapritinib tablet
Study: NCT02284594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text message
Description: series of text messages regarding influenza vaccination
Study: NCT01948622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mulungu
Description: 500 mg/single dose/1 hour before dental surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg/single dose/1 hour before dental surgery
Study: NCT01652560

Intervention type: DRUG
Intervention: bevacizumab
Description: The patients will be treated with Avastin combined neoadjuvant chemotherapy
Study: NCT01023750

Intervention type: DRUG
Intervention: Fenofibrate
Description: Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
Study: NCT03007576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RegStem
Description: RegStem, 1.5 ml, one injection
Study: NCT01401283

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: measurement of cardiac output and pulse pressure variation
Description: hemodynamic optimization according to cardiac index and pulse pressure variation
Study: NCT03015389

Intervention type: PROCEDURE
Intervention: Diagnostic Test
Description: WATS3D brush biopsy
Study: NCT02374554

Intervention type: DEVICE
Group type: OTHER
Intervention: Structured Light Plethysmography (Thora-3Di)
Description: Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period

Intervention type: DEVICE
Group type: OTHER
Intervention: BCI Capnograph 9004 (Smiths Medical)
Description: Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
Study: NCT03520660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: sofosbuvir/velapatasvir combination (Epclusa)
Study: NCT01621594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cannon Aquilion ONE CT system
Description: To test the diagnostic accuracy of low-radiation dose CT coronary angiography for detecting significant coronary artery stenosis and to determine the prognostic value of low-radiation dose CT coronary angiography for discriminating patient risk of death or major adverse cardiac events.
Study: NCT02181023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
Study: NCT04715802

Intervention type: PROCEDURE
Intervention: delayed breast reconstruction with autologous fat transplantation
Description: Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.